Find a Doctor

Partow Kebriaei

Physicians Referral Service
Hematology, Transplant Surgery, Internal Medicine
Female
Practicing approx. 24 years
Approx. age 50

Bio


Partow Kebriaei is a Hematologist and a Transplant Surgeon in Houston, Texas. She has been an author on 240 peer reviewed articles and participated in 3 clinical trials in the past 15 years. She is licensed to treat patients in TX.

Contact

Houston, TX 77030, US

Latest Advances


Latest Advance
Study
  • Condition: Large B-Cell Lymphoma
  • Journal: Blood advances
  • Treatment Used: Axicabtagene Ciloleucel (axi-cel)
  • Number of Patients: 100
  • Published —
This study analyzed patients with relapsed or refractory large B-cell lymphoma (LBCL) treated with standard of care axicabtagene ciloleucel (axi-cel).
Latest Advance
Study
  • Condition: Acute Myeloid Leukemia
  • Journal: Blood advances
  • Treatment Used: Melphalan- versus Busulfan-based Regimens
  • Number of Patients: 1413
  • Published —
The study researched the safety and effectiveness of melphalan- versus busulfan-based regimens for treating acute myeloid leukemia.
Latest Advance
Study
  • Condition: Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
  • Journal: The Lancet. Haematology
  • Treatment Used: Hyper-CVAD combined with Ofatumumab
  • Number of Patients: 69
  • Published —
This study tested the safety and efficacy of using hyper-CVAD combined with ofatumumab to treat patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
Latest Advance
Study
  • Condition: Myelofibrosis
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Hematopoietic Cell Transplant
  • Number of Patients: 0
  • Published —
This study evaluated low-dose, later escalated to high-dose (myeloablative conditioning), busulfan with fludarabine (Bu-Flu) in patients with myelofibrosis.
Latest Advance
Study
  • Condition: Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
  • Journal: Clinical lymphoma, myeloma & leukemia
  • Treatment Used: Venetoclax Combined With Chemotherapy
  • Number of Patients: 13
  • Published —
In this study, researchers evaluated the safety and effectiveness of venetoclax combined with chemotherapy for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Latest Advance
Study
  • Condition: CD19-Positive Lymphoid Tumors
  • Journal: The New England journal of medicine
  • Treatment Used: CAR-Transduced Natural Killer Cells
  • Number of Patients: 11
  • Published —
The study researched the safety and effectiveness of CAR-transduced natural killer cells for treating CD19-positive lymphoid tumors.
Latest Advance
Study
  • Condition: Acute Myeloid Leukemia
  • Journal: American journal of hematology
  • Treatment Used: Haploidentical Transplantation
  • Number of Patients: 143
  • Published —
This study tested the safety and efficacy of using haploidentical transplantation to treat patients with acute myeloid leukemia that have minimal/measurable residual disease at transplantation.
Latest Advance
Study
  • Condition: Adult Acute Lymphoblastic Leukemia
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Hematopoietic Cell Transplantation
  • Number of Patients: 0
  • Published —
The article discusses the safety and effectiveness of using hematopoietic cell transplantation (removing beneficial cells and replacing them in a different person or different area of the same person) for adult acute lymphoblastic leukemia.
Latest Advance
Study
  • Condition: Relapsed or Refractory Acute Lymphoblastic Leukemia
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment
  • Number of Patients: 101
  • Published —
In this study, researchers evaluated the outcomes of using inotuzumab ozogamicin followed by allogeneic stem cell transplantation for the treatment of acute lymphoblastic leukemia.
Latest Advance
Study
  • Condition: Hematopoietic Stem Cell Transplantation
  • Journal: The Lancet. Haematology
  • Treatment Used: fludarabine with a higher versus lower dose of time-sequential busulfan
  • Number of Patients: 98
  • Published —
The purpose of the study was to test the safety of timed-sequential deliver of low-dose versus high-dose myeloablative busulfan in older patients and patients with comorbidities.
Latest Advance
Study
  • Condition: Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL)
  • Journal: Cancer
  • Treatment Used: Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab
  • Number of Patients: 48
  • Published —
This study evaluated the outcomes of chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in first salvage.
Latest Advance
Study
  • Condition: Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem Cell Transplantation (ASCT)
  • Number of Patients: 125
  • Published —
This study was a phase 2 trial of gemcitabine, busulfan and melphalan (Gem/Bu/Mel) with autologous stem cell transplantation (ASCT) in patients with primary refractory or poor-risk relapsed Hodgkin lymphoma (HL) (ie, extranodal relapse or within 1 year of frontline therapy).
Latest Advance
Study
  • Condition: Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Myeloablative Allogeneic Transplantation
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Pretransplant Consolidation
  • Number of Patients: 524
  • Published —
This study compared adult patients with acute lymphoblastic leukemia (ALL) in complete remission (CR1) who received ?2 , 1, or 0 cycles of consolidation before myeloablative allogeneic hematopoietic cell transplantation (alloHCT).
Latest Advance
Study
  • Condition: Adults with Acute Lymphoblastic Leukemia (ALL)
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Total Body Irradiation (TBI) Pretransplant Conditioning
  • Number of Patients: 819
  • Published —
This study analyzed Total body irradiation (TBI) and busulfan (Bu) on outcomes of patients 18-60 years old with acute lymphoblastic leukemia (ALL) , in first or second complete remission (CR), undergoing HLA-compatible sibling, related, or unrelated donor hematopoietic cell transplantation (HCT).

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug, Biological
  • Participants: 24
  • Start Date: November 11, 2020
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug, Biological
  • Participants: 24
  • Start Date: June 26, 2020
Donor-Derived Very-Rapid Manufactured CD19-Specific T Cells for Lymphoid Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Device, Drug
  • Participants: 75
  • Start Date: May 8, 2017
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

All Publications
View All


Publication
Conference
  • Sponsor: American Society of Hematology (ASH)
  • Event Name: American Society of Hematology Annual Meeting and Exposition 2020
  • Published —
Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Contact

Houston, TX 77030, US

Affiliations

  • The University Of Texas M.d. Anderson Cancer Center

Credentials

  • Graduate InstitutionUniversity Of Texas Medical School At Houston
    1997
  • Licenses
    Internal Medicine in TX
  • Board Certifications
    Hematopoietic Cell Transplantation And Cellular Therapy

Insurance

Contact them to find out if they accept your insurance plan.